Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05889260 · ClinicalTrials.gov registry record
Speech Accessibility Project
A clinical trial of Parkinson Disease and Multiple System Atrophy, sponsored by University of Illinois at Urbana-Champaign.
- Completed
- Registry status
- 485
- Enrollment target
- 2
- Study locations
NCT05889260: Completed study of Parkinson Disease and Multiple System Atrophy, sponsored by University of Illinois at Urbana-Champaign.
NCT05889260 is a study of Parkinson Disease and Multiple System Atrophy that has completed, run by University of Illinois at Urbana-Champaign. The registered enrollment target is 485 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05889260, a study of Parkinson Disease and Multiple System Atrophy, has completed, sponsored by University of Illinois at Urbana-Champaign.
- COMPLETED
- Registry status
- 485 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of the Speech Accessibility Project at the University of Illinois Beckman Institute (https://speechaccessibilityproject.beckman.illinois.edu) is to collect, annotate, and curate a shared database of speech samples from people with atypical speech, and share this data set with researchers at other organizations. This two-year project plans to collect 1,200,000 speech samples from 2,000 people, each of whom will provide 600 samples. In Year 1, the initial focus will be people with Parkinson's. In Year 2, four more etiologies of interest will be recruited: Amyotrophic Lateral Sclerosis (ALS), Cerebral Palsy (CP), Down Syndrome (DS), and Stroke. UIUC will build an open-source software infrastructure to collect annotated speech samples and share these data in an appropriately secure fashion with researchers from our partner technology companies (and eventually, other organizations as well) so that they can use these data to improve their automatic speech recognition algorithms. This project promotes diversity, equity, and inclusion by helping technology companies to fully support all types of speech, and it is also more efficient and less burdensome for these specialized patient populations to have one centralized "collector" of speech samples.
Primary Outcome
Each participant records 600 sentences: 480 read sentences, and 120 spontaneous sentences recorded in response to 30 prompts.
Conditions Studied
Study Locations (2)
Colorado
- LSVT Global - Denver
Illinois
- University of Illinois at Urbana-Champaign - Urbana
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 485 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2025-07-31 |
What the finished NCT05889260 record still lists
NCT05889260 is an observational study that tracks outcomes without assigning an intervention. The registered 485 participants enrollment target is mid-sized for trials with a published cap, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (91% lower).
The record links to 4 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 0 interventions.
NCT05889260 reports a single indexed study location in Colorado, Illinois.
Frequently Asked Questions
What is clinical trial NCT05889260 about?
NCT05889260 is a clinical study titled "Speech Accessibility Project". The goal of the Speech Accessibility Project at the University of Illinois Beckman Institute (https://speechaccessibilityproject.beckman.illinois.edu) is to collect, annotate, and curate a shared database of speech samples from people with atypical speech, and share this data set with researchers at...
What is the current status of trial NCT05889260?
This trial is currently completed. The enrollment target is 485 participants. The study started on 2023-03-15. Estimated completion is 2025-07-31.
What conditions does trial NCT05889260 study?
This clinical trial studies the following conditions: Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Progressive Supranuclear Palsy.
Who is sponsoring clinical trial NCT05889260?
This trial is sponsored by University of Illinois at Urbana-Champaign, which has 129 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05889260 being conducted?
This trial has 2 study locations across Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05889260's enrollment target sits among peer trials
485 25th of 297 higher than 273 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07124910 · 485 participants · Phase 3
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
- NCT06420531 · 486 participants · NA
Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial
- NCT07097142 · 486 participants · Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- NCT05421741 · 484 participants · Phase 4
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI